

Title	Enhancing the clinical pharmacy service of a large teaching hospital: Development of a new clinical prioritisation tool
Authors	Clarke, Rebecca;Colleran, Maeve;Melanophy, Gail;Bermingham, Margaret
Publication date	2023-09-21
Original Citation	Clarke, R., Colleran, M., Melanophy, G. and Bermingham, M. (2023) 'Enhancing the clinical pharmacy service of a large teaching hospital: Development of a new clinical prioritisation tool', Exploratory Research in Clinical and Social Pharmacy, 12, 100335 (8 pp). https://doi.org/10.1016/j.rcsop.2023.100335
Type of publication	Article (peer-reviewed)
Link to publisher's version	https://doi.org/10.1016/j.rcsop.2023.100335 - 10.1016/j.rcsop.2023.100335
Rights	© 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). - http://creativecommons.org/licenses/by-nc-nd/4.0/
Download date	2026-08-19 09:29:19
Item downloaded from	https://hdl.handle.net/10468/15054



UCC

University College Cork, Ireland
 Coláiste na hOllscoile Corcaigh

Clinical Prioritisation Survey

Criteria used for Clinical Prioritisation in Pharmacy

Please reflect on the methods you commonly use to prioritise your patients. Think about what factors prompt you to prioritise a patient, **new or existing**, for immediate review, versus a patient who might be seen later in the day or the next day.

All survey responses are anonymous

* 1. Please select your top five features (columns) of the PCO which help you to prioritise patients

- | | |
|--|---|
| ☐ Antimicrobials | ☐ Oral anticoagulant task |
| ☐ Anticoagulants | ☐ Demographics (e.g. age, weight, CrCl) |
| ☐ High risk medicines | ☐ Visit (length of stay, admission date) |
| ☐ Medicines reconciliation task | ☐ Diagnoses |
| ☐ Allergies | ☐ VTE risk assessment form incomplete |
| ☐ Unverified medicines | ☐ INR level |
| ☐ Pharmacist notes (date last reviewed, follow-up points) | ☐ Capillary blood glucose level |

* 2. Please select your top five high risk medications or classes of medications as classified by EPR

- | | |
|--|--|
| ☐ Oral systemic anticancer therapy (SACT) or SACT placeholder | ☐ Methadone |
| ☐ Lithium | ☐ Insulin placeholder |
| ☐ Clozapine | ☐ Tocilizumab |
| ☐ Carbidopa/levodopa (+/- entacapone), co-beneldopa | ☐ SGLT2 inhibitors |

* 3. Please select your top five medications or medication classes you consider high priority in general

- | | |
|---|---|
| ☐ Anticoagulants | ☐ Immunosuppressants |
| ☐ Antiepileptics | ☐ Insulin |
| ☐ Antimicrobials | ☐ Intravenous potassium or other IV electrolytes |
| ☐ Antidepressants | ☐ Non-steroidal anti-inflammatory drugs |
| ☐ Antipsychotics | ☐ Opioids |
| ☐ Benzodiazepines | ☐ Oral anti-diabetic medicines |
| ☐ Corticosteroids | ☐ Parkinson's disease medications |
| ☐ Systemic anti-cancer therapy | |
| ☐ Other (please specify) | |

* 4. What number of unverified medications would you consider high priority (choose one)?

- | | |
|--|---|
| ☐ Any number of unverified medicines | ☐ > 10 unverified medicines |
| ☐ > 5 unverified medicines | ☐ > 15 unverified medicines |
| ☐ > 8 unverified medicines | ☐ I do not prioritise based on the number of unverified medicines |

* 5. Do you prioritise patients where you identify a drug-drug or drug-disease interaction with a suspected toxic or subtherapeutic effect?

- ☐ Yes
- ☐ No

* 6. Do you prioritise patients where you identify a drug-drug or drug-disease interaction where there is no suspected toxic or subtherapeutic effect?

- ☐ Yes
- ☐ No

* 7. What degree of polypharmacy do you consider high priority (choose one)?

- ☐ > 5 medicines
- ☐ > 10 medicines
- ☐ > 15 medicines
- ☐ I do not prioritise based on polypharmacy

* 8. What number of co-morbidities would you consider high priority (choose one)?

- ☐ > 1 comorbid conditions
- ☐ > 2 comorbid conditions
- ☐ > 3 comorbid conditions
- ☐ > 4 comorbid conditions
- ☐ I do not prioritise based on the number of co-morbid conditions

* 9. If you prioritise based on the number of co-morbidities, is this based off the diagnoses column in the PCO?

- ☐ Yes
- ☐ No
- ☐ I do not prioritise based on the number of co-morbid conditions

* 10. Please select your top five conditions that you consider high priority

- | | |
|--|---|
| ☐ Active cancer | ☐ Infection |
| ☐ Acute kidney injury | ☐ Ischaemic heart disease |
| ☐ Any unstable disease | ☐ Mental health history |
| ☐ Atrial fibrillation | ☐ Neurological disorder (e.g. Parkinson's disease, epilepsy or dementia) |
| ☐ Congestive heart failure | ☐ Nil by mouth or swallowing difficulties |
| ☐ Chronic kidney disease (defined as eGFR < 30ml/min) | ☐ Organ transplant |
| ☐ Diabetes | ☐ Over sedation |
| ☐ Drug related admission e.g adverse reaction | ☐ QT prolongation |
| ☐ Extreme weight (underweight or obese) | ☐ STEMI/NSTEMI |
| ☐ Falls or high risk of falls | ☐ Severe respiratory disease |
| ☐ Hepatic impairment | ☐ Stroke |
| ☐ Hyperlipidaemia | ☐ Transient Ischaemic Attack |
| ☐ Hypertension | ☐ Venous thromboembolism |
| ☐ Hypotension | |
| ☐ Other (please specify) | |

* 11. Do you prioritise your patient for review if they have abnormal lab results related to or affecting medication ?

- ☐ Yes
- ☐ No

* 12. Do you prioritise your patient for review if they have abnormal lab results not related to or affecting medication ?

☐ Yes

☐ No

* 13. Do you prioritise your patient for review if they are transferred to your ward from the intensive care unit or high dependency unit?

☐ Yes

☐ No

* 14. At what age threshold would you prioritise an older adult (choose one)?

☐ ≥ 65 years old

☐ ≥ 70 years old

☐ ≥ 75 years old

☐ I do not prioritise older adults

☐ Other (please specify)

* 15. Please select your top five patient-related or social risk factors that you consider high priority

☐ Dependant living situation e.g. nursing home

☐ Drug misuser

☐ Non-English-speaking

☐ Pregnancy and/or breastfeeding

☐ Poor historian / confused

☐ History of significant medication allergy

☐ Suspected non-adherence

☐ Recent hospitalisation (re-admission to hospital within 30 days of discharge)

☐ No fixed address

☐ Other (please specify)

Ideas & Opinions on Clinical Prioritisation

* 16. Do you use any other criteria or method, not mentioned in the survey, to help your clinical prioritisation? Please describe  0

* 17. What ideas do you have to enhance clinical prioritisation methods for pharmacists in SJH? This may or may not include ideas incorporating the EPMAR/PCO  0

Demographic Questions

* 18. Please select your grade of work  0

- ☐ Basic grade pharmacist
- ☐ Senior pharmacist
- ☐ Chief pharmacist

* 19. Please select how many years of experience you have in hospital pharmacy  0

- ☐ 0 - 3 years
- ☐ 4 - 7 years
- ☐ 8+ years

* 20. Please select how many years you have used the EPMAR or other electronic patient prescribing system (note Project Oak launched in SJH in October 2018)  0

- ☐ 0 - 3 years
- ☐ 4 - 7 years
- ☐ 8+ years